Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab. (16th July 2018)

• Record Type: Journal Article
• Authors: Bersanelli, Melissa; Gnetti, Letizia; Azzoni, Cinzia; Bottarelli, Lorena; Sverzellati, Nicola; Campanini, Nicoletta; Varotti, Elena; Corrado, Michele; Parziale, Raffaele; Rapacchi, Elena; Caruso, Giuseppe; Leonardi, Francesco; Silini, Enrico Maria; Buti, Sebastiano
• Is Part Of: Immunotherapy. Volume 10:Number 9(2018)
• Page Start: 743
• Page End: 752
• Publication Date: 2018-07-16
• Subjects: FHIT -- loss of heterozygosity -- renal cell carcinoma; Immunotherapy -- Periodicals; 615.37
• DOI: 10.2217/imt-2017-0160
• Languages: English
• ISSNs: 1750-743X

Abstract

Aim: We studied the possible clinical significance of loss of heterozygosity (LOH) at key tumor suppressor genes loci in advanced renal cancer patients treated with nivolumab.Methods: LOH study was performed on 3p14.2 ( FHIT gene); 3p21.3–21.2; 9p21 ( BDMF gene); 9p22 ( SH3GL2 gene).Results: Of 12 patients, 8 (67%) had LOH. The most affected gene was FHIT . All five patients with LOH at FHIT locus had good outcome, mean progression free survival of 6.8 months. The patients LOH negative at FHIT locus had mean progression free survival of 4 months, 67% were treatment refractory. Overall, 75% of patients with LOH of at least one gene had benefit; 75% of LOH negative cases were refractory.Conclusion: LOH at key tumor suppressor genes should be further investigated as predictive for immunotherapy.